Glargine trial promising for Mylan, Biocon

Mylan announced the beginning of phase-III trials of generic drug Glargine, which is a biosimilar version of Sanofi’s Lantus


(Photo Courtesy:

Glargine was developed by India's Biocon which was out-licensed to Mylan for further development.

According to Mylan, the trials have been initiated in August 2014 and is expected to culminate in June 2016.

The market for this drug is expected to be $3-4 billion worldwide.

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email